The Medical Letter website uses cookies. By continuing to browse this website you are agreeing to our use of cookies. Find out more      
The Medical Letter on Drugs and Therapeutics
Nebulized Glycopyrrolate (Lonhala Magnair) for COPD
The full article is available to subscribers Subscriber Login   

The FDA has approved an inhalation solution formulation of the long-acting antimuscarinic agent (LAMA) glycopyrrolate (Lonhala Magnair – Sunovion) for maintenance treatment of chronic obstructive pulmonary disease (COPD). The new formulation is delivered using a portable, handheld, electronic nebulizer. Glycopyrrolate is also available as a dry powder inhaler, both alone (Seebri Neohaler) and in combination with indacaterol (Utibron Neohaler), and as a metered-dose inhaler in combination with formoterol (Bevespi Aerosphere).1 Lonhala Magnair is the first nebulized LAMA to become available in the US.

CLINICAL STUDIES — The efficacy of nebulized glycopyrrolate was evaluated in two 12-week trials (GOLDEN 3 and 4) in 1294 patients with moderate to very severe COPD who were randomized to receive glycopyrrolate 25 mcg or 50 mcg or ... more      

The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Immediate Online access to current issue and archives from 1988 to the present
  • Mobile access to our mobile site and free apps for iOS, Android and Kindle
  • FREE online per issue CME/CE
Free trial offer
3 Free Issues of The Medical Letter on Drugs and Therapeutics mailed to your home or office PLUS online access.
Try a Free Trial Subscription
Purchase this article:
Title: Nebulized Glycopyrrolate (Lonhala Magnair) for COPD
Article code: 1545d
 Electronic, downloadable article - $25